Moderna Inc
0QF
Company Profile
Business description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Contact
325 Binney Street
CambridgeMA02142
USAT: +1 617 714-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4,700
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
Real estate share remains cheap despite losing airport legal battle.
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.
stocks
What happens if Tesla and SpaceX merge?
We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.90 | 28.90 | 0.32% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,649.65 | 400.36 | 1.65% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,727.83 | 2,510.56 | 3.91% |
| NZX 50 Index | 13,345.76 | 143.60 | 1.09% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,802.90 | 29.40 | 0.34% |
| SSE Composite Index | 4,034.59 | 47.58 | 1.19% |